Navigation Links
Rutgers biomaterial debuts in clinical trials of new stent
Date:10/18/2007

New Brunswick, N.J. A revolutionary, new biomaterial, developed at the New Jersey Center for Biomaterials (NJCBM) at Rutgers University, has moved from the lab bench to field testing in record time. This achievement, a product of a breakthrough methodology in biomaterials discovery, is the enabling technology behind a coronary stent undergoing its first-in-human clinical trial in Germany and in Brazil.

Stents are tiny tubes inserted into diseased arteries to keep them open. The stent being tested, designed by REVA Medical Inc. of San Diego, is intended to act as a temporary scaffold to support the blood vessel during the healing process and maintain blood flow. It subsequently dissolves, leaving the patient free of any permanent implant.

Rutgers Joachim Kohn is reporting on his new combinatorial biomaterials discovery process and the promise it holds for the medical device industry during TCT 2007 (Transcatheter Cardiovascular Therapeutics), the world's premier conference on interventional cardiology, which begins Saturday, Oct. 20 in Washington, D.C. Also reporting at the conference, Dr. Eberhard Grube of the HELIOS Heart Center in Germany describes the initial clinical experience from the RESORB trial that is evaluating the stents safety in approximately 30 patients at multiple sites in Germany and Brazil.

Fully degradable coronary stents have been explored for more than 20 years. But, according to Kohn, no clinically useful products could be developed, in part, because of the lack of polymers that could meet the extremely demanding performance requirements. Kohn and his team addressed this problem by developing a library of degradable polymers comprising 10,000 theoretically possible compositions and applying combinatorial methods to identify the best possible biomaterial. The resulting material was selected for use in combination with REVAs novel stent design.

Weve applied novel design and advanced biomaterials solutions to create a significant advance in stent technology, said Dr. Robert Schultz, REVAs president. This approach has allowed for us to bring it to the clinical stage quickly.

Our unconventional discovery process integrates combinatorial polymer libraries, high-throughput testing and computational modeling. This results in a much faster path to prototype development and a reduction in the cost and risk associated with the use of new, proprietary biomaterials, said Kohn, a Board of Governors Professor who directs the New Jersey Center for Biomaterials at Rutgers.

Michael J. Pazzani, vice president for research and graduate and professional education at Rutgers, spoke of the impact of Kohns work on the medical device industry. In addition to REVA, Rutgers has licensed the portfolio of Kohns patents to several other companies. One licensee was able to obtain FDA clearance for a new hernia repair device using one of Kohns polymers on a three-year track from concept to FDA market clearance, Pazzani said. Another is working with Kohn's combinatorial discovery process to identify an ideal polymer for their ophthalmic drug delivery device.

The significance of Kohns work is related to its general applicability to many different biomaterials design challenges as evidenced by the diversity of products being commercialized using this discovery process.

The scientific foundations of the new biomaterials discovery process are being developed with support to the New Jersey Center for Biomaterials and the Kohn Laboratory from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health.

In collaboration with REVA, Kohn and his colleagues developed a polymer that is exceptionally strong and highly suitable for stent applications. In addition, the material was designed to be radio-opaque so it is X-ray visible, a property critical to the proper placement of the stent in the artery. It is also biodegradable and biocompatible.

Pazzani said that reaching the clinical trial stage is an accomplishment for the university and a great source of pride. This is a major achievement for our state, a success story for our Office of Corporate Liaison and Technology Transfer, he said, and, Pazzani added, it is significant validation for the work of Rutgers scientists.


'/>"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers, the State University of New Jersey
Source:Eurekalert

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... New Freedom, PA (PRWEB) , ... April 22, ... ... of healthcare experience to his role as Vice President of Sales and Business ... direction of key GPO/IDN business partner engagements, business development, and strategic planning for ...
(Date:4/21/2017)... ... ... Providing broad access to life-saving drugs and rewarding the innovators who develop ... address this problem. , That was the message from Dana Goldman, PhD, Leonard D. ... of Southern California, who served as the keynote speaker for Western University of Health ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Chicago plastic surgeon, ... removal of osteoma. An osteoma is a benign bony lump located on the forehead ... and can cause difficulties with sight and pain. Dr. Shah has discovered an approach ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, an insurance ... throughout the greater Pittsburgh metropolitan region, is joining forces with the local chapter ... differently-abled children. , Variety the Children’s Charity is a national organization dedicated to ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The ... the 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary ... honored with the award at The Beryl Institute’s annual Patient Experience Conference ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology: